SCHEMBL256822

SCHEMBL256822

Cc1ccc(C(=O)c2ccccc2F)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
MAPK13 O15264 3/20 0.47
MAPK12 P53778 3/20 0.47
MAPK11 Q15759 3/20 0.47
MAPK14 Q16539 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RAB9A P51151 5/20 0.47
ALDH1A1 P00352 2/20 0.46
ALOX15 P16050 1/20 0.46
NPC1 O15118 2/20 0.45
PKM P14618 1/20 0.45
GRM4 Q14833 1/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11755563 0.86 CES2 (0.50) TP53MEN1KMT2ARAB9AALDH1A1
SCHEMBL7208739 0.86 RAB9A (0.59) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL23070442 0.84 HPGD (0.53) TP53MAPK13MAPK12MAPK11MAPK14
SCHEMBL11109843 0.84 KMT2A (0.52) TP53MEN1KMT2ARAB9AALDH1A1
SCHEMBL611947 0.83 RECQL (0.54) TP53MEN1KMT2ARAB9AALDH1A1
SCHEMBL29826380 0.82 AKR1C3 (0.57) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL2189708 0.81 ALDH1A1 (0.57) TP53MAPK13MAPK12MAPK11MAPK14
SCHEMBL2705741 0.81 MAPT (0.56) TP53MAPK13MAPK12MAPK11MAPK14
SCHEMBL10659109 0.80 HPGD (0.54) TP53KMT2ARAB9AALDH1A1ALOX15
SCHEMBL8609884 0.80 ALDH1A1 (0.52) TP53MEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 TP53 4509/4885MAPK13 1656/4885MAPK12 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.